Molecular mechanisms of estrogen action: Selective ligands and receptor pharmacology

Journal of Steroid Biochemistry and Molecular Biology

Volumn 74, Issue 5, 2000, Pages 279-285

  Katzenellenbogen, Benita S ^a,b   Choi, Inho ^a   Delage Mourroux, Regis ^a   Ediger, Tracy R ^b   Martini, Paolo G V ^a   Montano, Monica ^a   Sun, Jun ^a   Weis, Karen ^a   Katzenellenbogen, John A ^c  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

^c UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

Estrogen; Estrogen receptor pharmacology; SERMS

Indexed keywords

ADAPTOR PROTEIN; ANTIESTROGEN; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FULVESTRANT; HYDROXYTAMOXIFEN; LIGAND; RALOXIFENE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); REGULATOR PROTEIN; REPRESSOR PROTEIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STEROID RECEPTOR COACTIVATOR 1; TAMOXIFEN;

BREAST CANCER; CANCER PREVENTION; CONFERENCE PAPER; DRUG MECHANISM; DRUG RECEPTOR BINDING; ENZYME ACTIVITY; ESTROGEN ACTIVITY; ESTROGEN RESPONSIVE ELEMENT; ESTROGEN THERAPY; HUMAN; LIGAND BINDING; MENOPAUSE; NONHUMAN; RECEPTOR AFFINITY; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; TARGET CELL; TRANSCRIPTION REGULATION;

ESTROGEN ANTAGONISTS; ESTROGEN RECEPTOR MODULATORS; ESTROGENS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; LIGANDS; RECEPTORS, ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY;

EID: 0034735859     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(00)00104-7     Document Type: Conference Paper

References (57)

1. Estrogen receptors: Bioactivities and interactions with cell signaling pathways
2. Antiestrogens: Mechanisms of action and resistance in breast cancer
3. Estrogen actions in arteries, bone and brain
4. Nuclear hormone receptors: Ligand-activated regulators of transcription and diverse cell responses
5. Estrogen is a male and female hormone
6. Tripartite steroid hormone receptor pharmacology: Interaction with multiple effector sites as a basis for the cell- and promoter-specific action of these hormones
7. Role of co-activators and co-repressors in the mechanism of steroid/thyroid receptor action
8. The nuclear receptor superfamily: The second decade
9. Nuclear receptor coactivators and corepressors
10. Cell signaling and estrogens in female rat osteoblasts: A possible involvement of unconventional nonnuclear receptors
11. Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells
12. Estrogen-induced activation of mitogen-activated protein kinase requires mobilization of intracellular calcium
13. Cell membrane and nuclear estrogen receptors (ERs) originate from a single transcript: Studies of ERα and ERβ expressed in chinese ovary cells
14. 125I] bovine serum albumin conjugate
15. Structure-function analysis of the hormone binding domain of the human estrogen receptor by region-specific mutagenesis and phenotypic screening in yeast
16. Hormone binding and transcription activation by estrogen receptors: Analyses using mammalian and yeast systems
17. Human estrogen receptor mutants with altered estrogen and antiestrogen ligand discrimination
18. Identification of cysteine-530 as the covalent attachment site of an affinity labeling estrogen (ketononestrol aziridine) and antiestrogen (tamoxifen aziridine) in the human estrogen receptor
19. Mutagenesis of cysteines in the hormone binding domain of the human estrogen receptor: Alterations in binding and transcriptional activation by covalently and reversibly attaching ligands
20. Identification of two cysteines closely positioned in the ligand binding pocket of the human estrogen receptor: Roles in ligand binding and transcriptional activation
21. Identification of charged residues in an N-terminal portion of the hormone binding domain of the human estrogen receptor important in transcriptional activity of the receptor
22. Identification of amino acids in the hormone binding domain of the human estrogen receptor important in estrogen binding
23. Different residues of the human estrogen receptor are involved in the recognition of structurally diverse estrogens and antiestrogens
24. Determinants of ligand specificity of estrogen receptor-α estrogen versus androgen discrimination
25. Powerful dominant negative mutants of the human estrogen receptor
26. Repression of endogenous estrogen receptor activity in MCF-7 human breast cancer cells by dominant negative estrogen receptors
27. Adenovirus-mediated delivery of a dominant negative estrogen receptor gene abrogates estrogen-stimulated gene expression and breast cancer cell proliferation
28. Constitutively active human estrogen receptors containing amino acid substitutions for tyrosine 537 in the receptor protein
29. Mechanistic aspects of estrogen receptor activation probed with constitutively active estrogen receptors: Correlations with DNA and coregulator interactions and receptor conformational changes
30. Ligand-independent activation of the oestrogen receptor by mutation of a conserved tyrosine
31. An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer
32. Ligand-independent activation of the estrogen receptors α and β by mutations of a conserved tyrosine can be abolished by antiestrogens
33. Cloning of a novel estrogen receptor expressed in rat prostate and ovary
34. ERβ: Identification and characterization of a novel human estrogen receptor
35. Editorial: A new actor in the estrogen receptor drama - Enter ER-β
36. Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions
37. Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen
38. The carboxyl-terminal F domain of the human estrogen receptor: Role in the transcriptional activity of the receptor and the effectiveness of antiestrogens as estrogen antagonists
39. Ligand-dependent; transcriptionally productive association of the amino- and carboxyl-terminal regions of a steroid hormone nuclear receptor
40. Transcription activation by the human estrogen receptor subtype β (ERβ) studied with ERβ and ERα receptor chimeras
41. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β
42. Novel ligands that function as selective estrogens or antiestrogens for estrogen receptor-α or estrogen receptor-β
43. Estrogen receptor subtype-selective ligands: Asymmetric synthesis and biological evaluation of cis- and trans-5,11-eialkyl-5,6,11,12-tetrahydrochrysenes
44. Estrogen receptor null mice: What have we learned and where will they lead us?
45. Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene
46. Expression of estrogen receptor alpha and beta during mouse embryogenesis
47. Generation and reproductive phenotypes of mice lacking estrogen receptor β
48. Estrogen inhibits the vascular injury response in estrogen receptor α-deficient mice
49. Endocrine treatment of breast cancer in women
50. Endocrine pharmacology of antiestrogens as antitumor agents
51. Analysis of mechanisms that determine dominant negative estrogen receptor effectiveness
52. Molecular basis of agonism and antagonism in the oestrogen receptor
53. An estrogen receptor-selective coregulator that potentiates the effectiveness of antiestrogens and represses the activity of estrogens
54. The quinone reductase gene: A unique estrogen receptor-regulated gene that is activated by antiestrogens
55. Transcriptional regulation of the human quinone reductase gene by antiestrogen-liganded estrogen receptor-α and estrogen receptor-β
56. Differential ligand activation of estrogen receptors ERα and ERβ at AP1 sites
57. + exchanger regulatory factor